Ronen Stein

Ronen Stein

Auto-generated profile, based on publicly available information

Ronen Stein

Division of Gastroenterology, Hepatology, & Nutrition Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
OLOren Ledder
Oren Ledder
MDMichael Dolinger
Michael Dolinger
ADand Marla C. Dubinsky
and Marla C. Dubinsky
RSRonen Stein
Ronen Stein
SVSrisindu Vellanki
Srisindu Vellanki
CTChristos Tzivinikos
Christos Tzivinikos
Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of tofacitinib in pediatric UC. Methods: This is a retrospective review of children diagnosed with UC treated with tofacitinib from 16 pediatric centers internationally. The primary outcome was week 8 corticosteroid-free clinical remission (Pediatric Ulcerative Colitis Activity Index <10). Secondary outcomes were clinical response (≥20-point decrease in Pediatric Ulcerative Colitis Activity Index) at week 8, corticosteroid-free clinical remission at week 24, and colectomy rate and adverse safety events through to last follow-up. The primary outcome was calculated by the intention-to-treat principle. Results: We included 101 children with a mean age at diagnosis of 12.8 ± 2.8 years and a median disease duration of 20 months (interquartile range [IQR], 10-39 months). All had treatment failure with at least 1 biologic agent, and 36 (36%) had treatment failure with 3 agents. Median follow-up was 24 weeks (IQR, 16-54 weeks). Sixteen (16%) children achieved corticosteroid-free clinical remission at week 8, and an additional 30 (30%) demonstrated clinical response. Twenty (23%) of 88 children achieved corticosteroid-free clinical remission at week 24. A total of 25 (25%) children underwent colectomy by median 86 days (IQR, 36-130 days). No serious drug-related adverse events were reported; there was 1 case of herpes zoster and 2 cases of minor blood test perturbations. Conclusions: In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data.

17 August 2022 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RSRonen Stein
Ronen Stein
SDScott G. Daniel
Scott G. Daniel
RBRobert N. Baldassano
Robert N. Baldassano
KFKara Rd Feigenbaum
Kara Rd Feigenbaum
KKKelly Rdn Kachelries
Kelly Rdn Kachelries
KBKyle Bittinger
Kyle Bittinger

29 April 2025 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
SRSharmistha Rudra
Sharmistha Rudra
KKKanak Kennedy
Kanak Kennedy
SNSarah Neukrug
Sarah Neukrug
JHJing Huang
Jing Huang
DCDiana L. Cousminer
Diana L. Cousminer
RSRonen Stein
Ronen Stein

15 January 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
RSRonen Stein
Ronen Stein
DTDan Turner
Dan Turner
SHSéamus Hussey
Séamus Hussey
AKAysha Kawasmi
Aysha Kawasmi
OLOren Ledder
Oren Ledder
MCMaire A. Conrad
Maire A. Conrad
Background: The pharmacokinetics of biologic agents can differ between children and adults with inflammatory bowel disease (IBD), often necessitating modified paediatric dosing strategies.Aims: To define the exposure–response relationship of vedolizumab in the paediatric IBD VedoKids cohort including the effect of baseline clearance on deep biochemical remission (normal C‐reactive protein [CRP]/erythrocyte sedimentation rate [ESR] and steroid‐free remission) at 30 weeks, and to use population pharmacokinetic models to find the best matches between adult and paediatric pharmacokinetic profiles.Methods: We sought a pharmacokinetic model on 312 serum vedolizumab concentrations from 129 children, assisted by a published adult model as a Bayesian prior. We employed the model for exposure–response evaluation and for investigating doses in paediatric patients to match the adult exposure at the labelled dose.Results: At Week 30, 104/129 (81%) children (53% female and 47% Crohn disease) remained on vedolizumab, of whom 39 (31%) in the exposure‐response evaluation were in deep biochemical remission. Increased baseline drug clearance was associated with lower deep biochemical remission rates at Week 30 based on ESR/CRP (OR 0.47 [95% CI 0.2–1.05, p = 0.08]) and calprotectin < 100 μg/g (OR 0.13 [95% CI 0.1–0.79, p < 0.05]). Higher weight and lower serum albumin were associated with increased clearance (p < 0.001). Simulation models found that, for children ≤ 30 kg, tiered fixed dosing regimens best matched adult drug concentrations.Conclusions: Drug clearance was strongly influenced by serum albumin. Baseline clearance predicted deep biochemical remission at Week 30. Further investigation is needed to better understand optimal dosing strategies—especially for lower‐weight children receiving vedolizumab.